Angiostatic therapies are now routinely embedded in the daily clinical management of cancer. Although these agents clearly benefit patient survival rates, the effect is only moderate with sometimes considerable side effects. A major cause of failure in this respect is the induction of resistance and tolerability against these drugs. Most angiostatic drugs are tyrosine kinase inhibitors that aim to inhibit or neutralize the activity of tumour-produced growth factors. Frustrating the tumour cells in this way results in genetic adaptations in the cells, turning them into mutants that are dependent on other growth mechanisms. It may therefore be necessary to shift to another class of drugs that directly target the tumour vasculature. It is evident that improvement of future angiogenesis inhibitors can only arise from two efforts. First, through the identification of better targets, preferably specifically expressed in the tumour vasculature. Secondly, through the development of combination therapies. The present review highlights the current efforts and challenges in trying to develop effective angiostatic combination therapies.
Skip Nav Destination
Article navigation
December 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 17 2014
The emerging quest for the optimal angiostatic combination therapy
Arjan W. Griffioen;
Arjan W. Griffioen
1
*Angiogenesis Laboratory, Department of Medical Oncology, VU Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
1Correspondence may be addressed to either of these authors (emailaw.griffioen@vumc.nl or Patrycja.Nowak-Sliwinska@epfl.ch).
Search for other works by this author on:
Andrea Weiss;
Andrea Weiss
*Angiogenesis Laboratory, Department of Medical Oncology, VU Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
†Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), CH-1015 Lausanne, Switzerland
Search for other works by this author on:
Robert H. Berndsen;
Robert H. Berndsen
*Angiogenesis Laboratory, Department of Medical Oncology, VU Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
†Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), CH-1015 Lausanne, Switzerland
Search for other works by this author on:
U. Kulsoom Abdul;
U. Kulsoom Abdul
*Angiogenesis Laboratory, Department of Medical Oncology, VU Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
Search for other works by this author on:
Marije T. te Winkel;
Marije T. te Winkel
*Angiogenesis Laboratory, Department of Medical Oncology, VU Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
Search for other works by this author on:
Patrycja Nowak-Sliwinska
Patrycja Nowak-Sliwinska
1
*Angiogenesis Laboratory, Department of Medical Oncology, VU Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
†Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), CH-1015 Lausanne, Switzerland
1Correspondence may be addressed to either of these authors (emailaw.griffioen@vumc.nl or Patrycja.Nowak-Sliwinska@epfl.ch).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
July 18 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (6): 1608–1615.
Article history
Received:
July 18 2014
Citation
Arjan W. Griffioen, Andrea Weiss, Robert H. Berndsen, U. Kulsoom Abdul, Marije T. te Winkel, Patrycja Nowak-Sliwinska; The emerging quest for the optimal angiostatic combination therapy. Biochem Soc Trans 1 December 2014; 42 (6): 1608–1615. doi: https://doi.org/10.1042/BST20140193
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.